Patients with neurological symptoms associated with COVID-19 are six times more likely to die
Patients with clinically diagnosed neurological symptoms associated with COVID-19 are six times more likely to die in the hospital than those without the neurological complications, according to an interim analysis from the Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID).
A paper published today in
JAMA Network Open presents early results of the global effort to gather information about the incidence, severity and outcomes of neurological manifestations of COVID-19 disease. Very early on in the pandemic, it became apparent that a good number of people who were sick enough to be hospitalized also develop neurological problems, said lead author Sherry Chou, M.D., M.Sc., principal investigator of the consortium and associate professor of critical care medicine, neurology, and neurosurgery at the University of Pittsburgh School of Medicine and UPMC.
SHARE
The
Global Consortium Study of Neurologic Dysfunction in Covid-19 says hospital patients with clinically diagnosed neurological signs are six times more likely to die than those without.
Read More Very early on in the pandemic it became apparent that a good number of people who were sick enough to be hospitalised also developed neurological problems, said Dr Sherry Chou, lead author and associate professor of critical care medicine, neurology and neurosurgery at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Centre (UPMC). A year later we are still fighting an unknown invisible enemy and, like in any battle, we need intel – we have to learn as much as we can about neurological impacts of Covid-19 in patients who are actively sick and in survivors.
Date Time
80% of Hospitalized COVID Patients Have Neurological Issues
Patients with clinically diagnosed neurological symptoms associated with COVID-19 are six times more likely to die in the hospital than those without the neurological complications, according to an interim analysis from the Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID).
A paper published today in JAMA Network Open presents early results of the global effort to gather information about the incidence, severity and outcomes of neurological manifestations of COVID-19 disease.
“Very early on in the pandemic, it became apparent that a good number of people who were sick enough to be hospitalized also develop neurological problems,” said lead author Sherry Chou, M.D., M.Sc., principal investigator of the consortium and associate professor of critical care medicine, neurology, and neurosurgery at the University of Pittsburgh School of Medicine and UPMC. “A year later, we are stil
JAMA Network Open:
JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
Share